BioAdaptives Statistics
Total Valuation
BioAdaptives has a market cap or net worth of 225,763. The enterprise value is 558,002.
| Market Cap | 225,763 |
| Enterprise Value | 558,002 |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAdaptives has 12.01 million shares outstanding. The number of shares has increased by 2.66% in one year.
| Current Share Class | 12.01M |
| Shares Outstanding | 12.01M |
| Shares Change (YoY) | +2.66% |
| Shares Change (QoQ) | +7.40% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | n/a |
| Float | 11.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.76 |
| PB Ratio | -0.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.50 |
| EV / Sales | 71.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.17 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.82 |
| Interest Coverage | -26.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -828.24% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 77.22% |
| Weighted Average Cost of Capital (WACC) | 9.20% |
| Revenue Per Employee | 7,851 |
| Profits Per Employee | -1.11M |
| Employee Count | 1 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.57% in the last 52 weeks. The beta is 1.05, so BioAdaptives's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -66.57% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 47.66 |
| Average Volume (20 Days) | 32,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, BioAdaptives had revenue of 7,851 and -1.11 million in losses. Loss per share was -0.12.
| Revenue | 7,851 |
| Gross Profit | 4,914 |
| Operating Income | -1.13M |
| Pretax Income | -1.11M |
| Net Income | -1.11M |
| EBITDA | -1.13M |
| EBIT | -1.13M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 59,273 in cash and 391,396 in debt, with a net cash position of -332,123 or -0.03 per share.
| Cash & Cash Equivalents | 59,273 |
| Total Debt | 391,396 |
| Net Cash | -332,123 |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -1.47M |
| Book Value Per Share | -0.13 |
| Working Capital | -1.48M |
Cash Flow
In the last 12 months, operating cash flow was -460,735 and capital expenditures -18,000, giving a free cash flow of -478,735.
| Operating Cash Flow | -460,735 |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -478,735 |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | 62.59% |
| Operating Margin | -14,410.84% |
| Pretax Margin | -14,091.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAdaptives does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.66% |
| Shareholder Yield | -2.66% |
| Earnings Yield | -490.04% |
| FCF Yield | -212.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 23, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jan 23, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
BioAdaptives has an Altman Z-Score of -155.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -155.45 |
| Piotroski F-Score | 3 |